Clinical Trial

A Study of [14C]-LY4064809 in Healthy Participants

Completed Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to determine in healthy participants the percentage of LY4064809 that enters bloodstream after oral administration. Blood tests will be performed to investigate how the body processes the study drug. For each participant, the study will last about 21 days, not including screening. Participants will remain in the clinical research center for 14 days.
Protocol Amendment History 3 changes
critical Trial completed 2026-06-09
notable Enrollment reduced: 8 -> 7 participants 2026-06-09
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-05-23
Trial Details
NCT Number NCT07519525
Lead Sponsor Eli Lilly and Company
Conditions Healthy
Enrollment 7 participants
Start Date 2026-03-27
Primary Completion 2026-05-26 (estimated)
Study Completion 2026-05-26 (estimated)
Updated on ClinicalTrials.gov 2026-06-08